Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472565 | 0.91 | CA1 (0.35) | BRD4CA1CA2USP30 | |
| SCHEMBL10192750 | 0.86 | CA1 (0.33) | CA1CA2ORAI1MEN1KMT2A | |
| SCHEMBL10193102 | 0.82 | CA1 (0.33) | CA1CA2ORAI1MEN1KMT2A | |
| SCHEMBL10285770 | 0.82 | CA1 (0.35) | CA1CA2ORAI1 | |
| SCHEMBL10039250 | 0.78 | CA1 (0.37) | BRD4CA1CA2ORAI1 | |
| SCHEMBL472692 | 0.78 | CA1 (0.37) | BRD4CA1CA2ORAI1 | |
| SCHEMBL472650 | 0.77 | CA1 (0.39) | CA1CA2ORAI1 | |
| SCHEMBL472672 | 0.77 | CA1 (0.36) | CA1CA2 | |
| SCHEMBL10155877 | 0.77 | CA1 (0.40) | BRD4CA1CA2USP30ORAI1 | |
| SCHEMBL10193735 | 0.76 | CA1 (0.35) | CA1CA2ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029037-A1 | ANIMAL ECTOPARASITE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029037-A1 | ANIMAL ECTOPARASITE-CONTROLLING AGENT | H1-3, EEF1A1, H1-4 | BRD4 114/4885CA1 866/4885CA2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.